Synthetic biology startup AbSci raises $65M to expand ‘Protein Printing’ tech
Vancouver, Wash.-based biotech company AbSci raised an additional $65 million to help grow its synthetic biology platform. The company’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin.
The AbSci platform is composed of two products: SoluPro, a synthetic biology platform based on genetically engineered E. coli, and purification platform SoluPure. SoluPro uses the natural processes of E. coli bacteria to build complex molecules inside the bacteria itself.